Viropro, Inc. Appoints Michelle Peake to Chief Executive Officer of Alpha Biologics Sdn Bhd Subsidiary Based in Penang, Malay...
03 10월 2011 - 9:07PM
Business Wire
VIROPRO (VPRO.PK) today announced the appointment of
Ms. Michelle Peake to the position of CEO of its wholly-owned
subsidiary Alpha Biologics Sdn. Bhd. facility based in Penang,
Malaysia. In her new role, Ms. Peake, who was formerly COO of Alpha
Biologics, will additionally head business development activities
for Viropro and Alpha in the Asian markets, a key part of the
Company’s near-term growth strategy.
Ms. Peake, who will be based in Penang, will provide Viropro
with her 16 years of experience in the research and development and
GMP manufacturing of biologics and biopharmaceutical markets with
such companies as Cambridge Cognition and Xenova (UK), and Agenix
Ltd. (Australia).
According to Dr. Rajiv Datar, President and CEO of Viropro,
“Recognizing the potentially great client demand for our GMP-based
mammalian cell clinical and production services in Penang, we are
delighted to have Michelle’s world-class leadership in biologics
and biopharmaceuticals available to drive our growth plan both in
Malaysia and throughout the Asian markets.”
Ms. Peake has just recently been appointed to the Industry
Advisory Panel of the Science University for Malaysia, and will be
the moderator for the biotech financing session at BioMalaysia
2011. She has also been asked to be a session chair at World
Congress of Industrial Biotechnology, Xi’an, and has been invited
to speak at the International Congress of Antibodies-2012,
Beijing.
Company also announces it has filed its September 2010, 10Q and
has initiated the YE audit process. As soon as the audited
financials are filed, the Company will call for a stockholders
meeting. As previously mentioned, the Company is seeking to return
to full disclosure status on an expedited basis.
An updated factsheet is available for review and download on the
Company’s website at www.viropro.com.
About Viropro, Inc.:
Viropro, Inc. conducts operations through its subsidiaries
Viropro International Inc., Biologics Process Development, Inc.,
Alpha Biologics Ltd. and Alpha Biologics Sdn. Bhd. Viropro’s
principal objective is to provide high-yield development and GMP
manufacturing services to biopharmaceutical companies in global
markets with unmet medical and/or market needs. The Company
specializes in the transfer of its core and proprietary
technologies for industrial production of biopharmaceutical
therapeutic proteins for the treatment of various diseases
including cancer, diabetes, hepatitis and multiple sclerosis.
(www.viropro.com)
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the
matters discussed in this press release contain forward-looking
statements that involve risks and uncertainties, which are subject
to section 27A of the Securities Act of 1933 and section 21E of the
Exchange Act of 1934, and are subject to safe harbor created by
these sections. Any statements that express or involve discussions
with respect to predictions, beliefs, plans, projections,
objectives, goals, assumptions of future events or performances are
not statements of historical fact and may be "forward-looking
statements." Forward-looking statements in this release may be
identified through the use of such words as "expects,"
"anticipates," "estimates," "believes," or statements indicating
certain actions "may," "could," or "might" occur. Actual results,
performance or achievements could differ materially from those
anticipated in such forward-looking statements, which involve
numerous risks and uncertainties, including the Company's ability
to market its products and services in a competitive environment as
well as other factors.
Viropro (CE) (USOTC:VPRO)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Viropro (CE) (USOTC:VPRO)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
